(Mal)nutrition and liverdisease

Similar documents
CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

HCV care after cure. This program is supported by educational grants from

ESPEN Congress Madrid 2018

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Healthy Liver Cirrhosis

9th Paris Hepatitis Conference

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

The Adverse Impact of Sarcopenia and Visceral Fat Deposition on the Course of Hepatocellular Carcinoma and the Role of Nutritional Interventions

Cirrhosis: Let s get moving!

Evidence Analysis Library Research Project

Non-Alcoholic Fatty Liver Disease

La gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi. Simona Landonio I Div Mal inf H Sacco Milano

SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES

Worldwide Causes of HCC

NUTRITIONAL OPTIMIZATION IN PRE LIVER TRANSPLANT PATIENTS

Cirrhosis is different from Fibrosis

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

ENCORE-PH Top-line Results

Liver transplant: what is left after the viruses

Jong Young Choi, M.D.

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate

REVIEW ARTICLE. Andres Duarte-Rojo, 1 Astrid Ruiz-Margain, 3 Aldo J. Monta~no-Loza, 4 Ricardo U. Macıas-Rodrıguez, 3 Arny Ferrando, 2 and W.

Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Changing epidemiology of HCC in Italy

Terapia anticoagulante nelle trombosi splancniche

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Steatosi epatica ed HCV

Nutrition Status pre Liver Transplant and Length of Hospital Stay post Liver Transplant

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?

Bariatric Surgery and Liver Transplantation

Nutrition Management of End- Stage Liver Failure

Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt

Copyright 2014 ChaBiotech. All Rights Reserved. 차의과학대학교분당차병원소화기내과이주호, MD, PhD

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Worldwide Causes of HCC

Treatment of chronic hepatitis delta Case report

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

B C Outlines. Child-Pugh scores

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

Antiviral treatment in HCV cirrhotic patients on waiting list

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Liver Transplantation Evaluation: Objectives

Screening for Portal Hypertension in Cirrhosis

Therapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH

NAFLD & NASH: Russian perspective

Learning Objectives. After attending this presentation, participants will be able to:

The place of bariatric surgery in NASH: can we extend the indications? - No

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Prospective Study on Efficacy of Oral Supplement of Branched-Chain Amino Acid Granules on the Nutritional Status of the Cirrhotics

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

The Liver for the Nonhepatologist

Clinical Nutrition in the 21st Century Malnutrition, sarcopenia and cachexia

Life After SVR for Cirrhotic HCV

Professor Norbert Bräu

Hepatitis C Virus and Metabolism

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Case 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan

Nutritional Issues In Advanced Liver Disease. Corrie Clark, RDN, LD

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

PREVALENCE OF NAFLD & NASH

Approved regimens for cirrhotic patients

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

Muscle. Sarcopenia. Muscle mass. Muscle matters! sarx flesh. penia deminished. low skeletal muscle mass. 640 muscles. contraction = movement

Hepatology for the Nonhepatologist

Nutritional Issues in Cholestatic Disease

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Follow-up of pediatric chronic liver disease

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation

Future strategies with new DAAs

Organ allocation for liver transplantation: Is MELD the answer? North American experience

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

Autoimmune Hepatitis: Defining the need for Liver Transplantation

Hepatocellular Carcinoma Surveillance

Hepatology For The Nonhepatologist

The Liver for the Nonhepatologist

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

Bariatric Surgery For Patients With End-Organ Failure

Management of Cirrhosis Related Complications

Meet the Professor: HIV/HCV Coinfection

Hepatitis C Update on New Treatments

Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

A pathologist, a radiologist and a hepatologist walked into a bar

How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu

Patterns of abnormal LFTs and their differential diagnosis

Accepted Article. Electronic word count: Number of Figures: 2. Number of Tables: 4. List of Abbreviations: HE - Hepatic encephalopathy

Management of Decompensated Chronic Hepatitis B

Antiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider?

Transcription:

(Mal)nutrition and liverdisease Giulio Marchesini Alma Mater Università di Bologna SSD Malattie del Metabolismo e Dietetica Clinica

Disclosures Giulio Marchesini Advisory Board: Eli Lilly, Gilead Honoraria: Sanofi, Merck Sharp & Dome, Novartis Clinical Studies: Eli Lilly, Sanofi, Novo Nordisk, GILEAD, GENFIT, Jannsen, Glaxo

Sommario (Mal)nutrizione delle malattie epatiche Metodi di valutazione Passato, presente e futuro Stato nutrizionale e outcomeclinico Cirrosi Trapianto di fegato Trattamento Diete speciali/perdita di peso

Anand, JClinExpHepatol2017 Malnutrition in cirrhosis

Protein-Calorie Malnutrition Percent ideal weight (%) Diagnostic Parameters Triceps Skinfold Thickness ( 12.5 mm) Mid-Arm Muscle Circumference (MAMC 25.3 cm) Creatinine-Height Index (%) Albumin ( 35 g/liter) Transferrin ( 180 mg/dl) Total Lymphocyte Count ( 1500 cells/mm 3 ) Delayed Cutaneous Hypersensitivity to a Battery of Skin Tests (DNCB or others) Mendenhall, Am J Clin Nutr 1986

Metodi più accessibili Antropometria Bioimpedenzometria

Nutritional Status in Cirrhosis by Etiology Alcohol-related N = MAMA < 5th percentile MAFA < 5th percentile Males 381 37.7 10.5 Females 64 4.7 42.2 Virus-B-related Males 187 31.7 9.2 Females 170 9.9 34.5 Cryptogenic Males 175 28.8 8.7 Females 221 3.2 14.5 Italian Multicenter Cooperative Project J Hepatol 1994

Nutritional Status in Cirrhosis All Cases Severe Malnutrition Moderate Malnutrition No Malnutrition Over Nutrition Males 11.4 21.4 49.4 17.8 Females 6.8 20.5 43.6 29.2 C-P Class A - Males 3.8 14.2 59.0 23.1 A - Females 3.8 16.4 47.5 32.4 B - Males 15.0 26.1 44.8 14.1 B - Females 9.0 27.1 38.1 25.8 C - Males 27.7 33.8 29.2 9.2 C - Females 20.0 26.7 35.6 17.8 Italian Multicenter Cooperative Project J Hepatol 1994

Merli, Hepatology 1996 1053 pts with cirrhosis, 5-yr f-up, 419 events

MUST Calculator (Malnutrition Universal Screening Tool)

Recommended cut-points for weakness and low muscle mass for men and women Cut-point Men Women Grip strength adjusted for BMI (GS BMI ) < 1.00 < 0.56 Appendicular lean body mass adjusted for BMI (ALM BMI ) Skeletal muscle index adjusted for weight (SMI weight ) < 0.789 < 0.512 < 29.0 < 22.9 GS BMI and ALM BMI cutpoints were identified by the NHI Sarcopenia Project. SMI weight cutpoints have been defined by BIA as SMI values below 2 standard deviation of a normal healthy population, where SMI% = total appendicular skeletal muscle mass (kg) / body weight (kg) 100.

Combined nutritional assessment in ptson the waiting list for OLT Ribeiro, Nutrition 2018

Mazurak, LiverTransplant2017 CT-assessed myosteatosis

Koo, J Hepatol 2017 Sarcopeniaand NAFLD severity

Sarcopeniaand NAFLD severity Multivariate model 1 was adjusted for age, gender, BMI, smoking, hypertension, and diabetes. Multivariate model 2 was adjusted for lipid profile and ALT + factors included in model 1. Multivariate model 3 was adjusted for hscrp +factors included in model 2. Multivariate model 4 was adjusted for HOMA-IR + factors included in model 2. Koo, J Hepatol 2017

Sarcopenia& fibrosis in NAFLD (KNHANES 2008-11 cohort: 2761/9676 subjects) Sarcopenia index (SI) calculated as: SI = total ASM (kg)/bmi (kg/m 2 ). Sarcopenia defined as SI <0.789 in men and <0.521 in women. NFS, Fib-4 & Forns Lee, Hepatology 2016

225 consecutive patients with histological diagnosis of NAFLD. Skeletal muscle index (SMI %) assessed by BIA. Sarcopeniadefined as SMI 37 in males and 28 in females. Petta, Alim Pharmacol Ther 2017

Sommario (Mal)nutrizione delle malattie epatiche Passato, presente e futuro Metodi di valutazione Stato nutrizionale e outcomeclinico Cirrosi Trapianto di fegato Trattamento Diete speciali/perdita di peso

Obesity- and sarcopenia-associated risks Atkins et al, J Am Geriatr Soc 2014

Clinical decompensation (%) 161 patients with compensated cirrhosis, followed until CD (ascites, hepatic encephalopathy, or variceal hemorrhage), or until September 2002 (median follow-up, 59 months) Etiology of cirrhosis: Viral, 68%; Alcohol, 22%; Crypto, 5%; Others, 5% Berzigotti, Hepatology 2017

Sarcopenia& survival in cirrhosis and HCC Cirrhosis HCC Montano-Loza, World J Gstroenterol 2014

Sarcopeniaand survival in the waiting list for OLT 396 pts newly listed for OLT in 2012 Carey, Liver Transplantation 2017

Adults with cirrhosis evaluated for OLT in the perid 2002-13, University of Alberta, Edmonton, Canada Montano-Loza, J Cachexia, Sarcopenia & Muscle 2016

669 cirrhotic patients consecutively evaluated for liver transplantation. Skeletal muscle index at the third lumbar vertebra (L3 SMI) was measured by computed tomography, and sarcopeniawas defined using previously published gender and body mass index specific cutoffs. Sarcopeniawas present in 298 patients (45%). By Cox regression analysis adjusted for age, gender, and hepatocellular carcinoma, both MELD and the L3 SMI were associated with mortality. Modification of MELD to include sarcopeniais associated with improved prediction of mortality in patients with cirrhosis, primarily in patients with low MELD scores. Montano-Loza, Clin Transl Gastroenterol 2015

VATI & HCC-free survival in cirrhosis Patients with cirrhosis (n = 678; 457 male) who were assessed for LT (289 with HCC) were evaluated for body composition analysis. Patients who underwent LT (n = 247, 168 male) were subsequently evaluated for body composition, and 96 of these patients (78 male) had HCC. Montano-Loza, Hepatology 2018

VATI & HCC-free survival in cirrhosis In male patients with HCC who underwent LT, a VATI 65 cm 2 /m 2 adjusted for Milan criteria was independently associated with higher risk of HCC recurrence (HR, 5.34; 95% CI, 1.19-23.97; P=0.03). Montano-Loza, Hepatology 2018

Survival (%) Both sarcopeniaand myosteatosiscause an excess of death rate for sepsis Montano-Loza, J Cachexia, Sarcopenia & Muscle 2016

Sommario (Mal)nutrizione delle malattie epatiche Passato, presente e futuro Metodi di valutazione Stato nutrizionale e outcomeclinico Cirrosi Trapianto di fegato Trattamento Diete speciali/perdita di peso

BCAA Italian Study Group -Results Cumulative Event-free Rates 1.0 0.9 0.8 0.7 0.6 0.5 0 3 6 9 12 15 Months BCAA M-DXT; P = 0.108 L-ALB; P = 0.034 Marchesini, Gastroenterology 2003

Meta-analysis on the effect of enteral BCAA vs. PL or control diets for hepatic encephalopathyin randomized controlled trials. *risk difference (RD) with 95% confidence interval (CI) Hayashi 1991 Horst 1984 Marchesini 1990 Marchesini 2003 Muto 2005 Plauth 1993 Les 2011 Overall NOTE: Weights are from random effects analysis RD (95% CI) 0.34 (0.15, 0.52) 0.24 (0.01, 0.48) 0.45 (0.23, 0.66) 0.09 (-0.11, 0.28) 0.05 (-0.29, 0.38) -0.01(-0.24, 0.22) 0.28 (-0.01, 0.56) 0.21 (0.09, 0.34) Weight 17.63 14.15 15.46 17.02 9.57 14.50 11.67 100.00-0.75 0 0.75 Gluud, JNutr2013

Meta-analysis on the effect of enteral BCAA vs.pl or control diets for mortality in trials on patients with HE *risk difference (RD) with 95% confidence interval (CI) Horst 1984 Marchesini 1990 Marchesini 2003 Muto 2005 Plauth 1993 Egberts Les 2011 Overall NOTE: Weights are from random effects analysis RD (95% CI) 0.06 (-0.08, 0.20) -0.06(-0.15, 0.04) 0.04 (-0.10, 0.18) -0.19(-0.48, 0.11) 0.00 (-0.15, 0.15) 0.00 (-0.16, 0.16) 0.01 (-0.27, 0.28) -0.01(-0.07, 0.04) Weight 15.57 34.60 16.10 3.59 13.49 12.52 4.13 100.00-0.5 0 0.5 Gluud, JNutr2013

Optimizing nutritional support in the setting of cirrhosis Perumpail, Nutrients 2017

Conceptual framework of the relation between nutritional status and physical fitness in ESLD Duarte-Rojo, Liver Transplantion 2018 Physical deconditioning, determined by a low CPE (cardiopulmonary endurance), and sarcopenia, a surrogate for progressive malnutrition, are cofactors leading to functional deterioration. As physical deconditioning progresses, patients exercise less and use less energy as part of NEAT. Frailty is conceptualized as the extreme of functional deterioration, leading to clinical outcomes.

Raccomandazioni per l apporto di proteine e esercizio fisico (adulti > 65 anni) Recommendations For healthy older adults, we recommend a diet that includes at least 1.0 to 1.2 g protein/kg body weight/day. For certain older adults who have acute or chronic illnesses, 1.2 to 1.5 g protein/kg body weight/day Consider may be indicated, with even higher intake for individuals renal with severe illness or injury. function! We recommend daily physical activity for all older adults, as long as activity is possible. We also suggest resistance training, when possible, as part of an overall fitness regimen. Deutz NEP et al., Clin Nutr 2014

Lifestyle intervention in cirrhosis: The SportDiet Study A prospective, uncontrolled pilot study in 60 patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [HVPG] 6 mm Hg), and body mass index (BMI) 26 kg/m 2. All were enrolled in an intensive 16-week LS intervention program (personalized hypo-caloric normoproteic diet and 60 min/wk of supervised PA). Changes in HVPG and BW were predefined as clinically relevant if 10% and 5%, respectively. Reassessment after 6 moin 50 cases. Etiology of cirrhosis: Viral, 18; Alcohol; 19, NAFLD, 12; Autoimmune, 1 Berzigotti, Hepatology 2017

Exercise model for patients with ESLD Duarte-Rojo,, Liver Transplantion 2018